From: Clinical characteristics of four cancer patients with SARS-CoV-2 infection in Wuhan, China
Clinical characteristics | Case 1 | Case 2 | Case 3 | Case 4 |
---|---|---|---|---|
Sex | Female | Female | Male | Male |
Age (years) | 48 | 78 | 54 | 37 |
Date of admission | 21 December 2019 | 18 January 2020 | 13 January 2020 | 14 January 2020 |
Date of COVID-19 diagnosis | 26 January 2020 | 25 January 2020 | 23 January 2020 | 1 February 2020 |
Underlying diseases | ||||
 Hypertension | No | Yes | No | No |
 Cardiovascular disease | No | Yes | No | No |
 COPD | No | Yes | No | No |
 HBV infection | No | No | Yes | Yes |
Tumor type | Breast cancer | B-CLL | Rectal cancer | HCC |
Tumor related therapy | ||||
 Chemotherapy | Yes | No | No | Yes |
 Radiotherapy | Yes | No | No | No |
 Surgery | Yes | No | Yes | Yes |
 Date of surgery | 25 June 2019 | / | 16 January 2020 | 20 January 2020 |
Dates of fever (day after admission) | Day 35, Day 36 | Day 6–Day 17 | Day 7–Day 11 | Day 17–Day 24 |
Maximum temperature | 38 °C | 39 °C | 39.5 °C | 39 °C |
Clinical type of COVID-19 | Mild | Severe | Common | Severe |
Anti-microbe therapy | ||||
 Antiviral | No | Oseltamivir | Oseltamivir | Oseltamivir Arbidol |
 Antibacterial | Ceftriaxone | Cefoperazone and sulbactam Linezolid | Meropenem Moxifloxacin | Imipenem and cilastatin Moxifloxacin |
 Antifungal | No | Caspofungin | No | Caspofungin |
Methylprednisolone | No | 40 mg/day | No | 40 mg/day |
Oxygen therapy | No | Noninvasive ventilation | Nasal catheter | High-flow oxygen |
Minimal oxygenation index (mmHg) | NA | 112 | NA | 261 |
ICU admission | No | Yes | No | Yes |
Clinical outcomes | Recovery of COVID-19; Discharge from hospital | Dead | Recovery of COVID-19; Discharge from hospital | Remission of COVID-19; Therapy in hospital |